<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 29, 2000
VIROPHARMA INCORPORATED
-----------------------
(Exact name of issuer as specified in charter)
<TABLE>
<S> <C> <C>
DELAWARE 0-021699 23-2789550
(State or Other (Commission (I.R.S. Employer
Jurisdiction file Identification
of Incorporation or number) Number)
Organization)
</TABLE>
405 EAGLEVIEW BOULEVARD
EXTON, PENNSYLVANIA 19341
(Address of principal executive offices)
(610) 458-7300
(Registrant's telephone number, including area code)
<PAGE>
Item 5 - Other Events.
As is more fully described in the attached press release that is
incorporated herein by reference, on August 29, 2000, ViroPharma Incorporated
("ViroPharma") announced the appointment of Ellen C. Cooper, M.D. as vice
president, clinical and regulatory affairs.
This report, including the press release attached hereto, contains forward-
looking statements, including statements relating to the Company's ongoing
efforts to obtain regulatory approval for and commercialize its product
candidates. Certain of ViroPharma's product candidates, including pleconaril,
currently are in clinical trials. There can be no assurance that planned or
ongoing clinical trials can be successfully concluded or concluded in accordance
with the Company's anticipated schedule. The conduct of clinical trials and
acquiring regulatory approval for investigational pharmaceutical products are
subject to risks and uncertainties. Neither the FDA nor any other regulatory
authority has approved pleconaril or any of ViroPharma's other product
candidates for commercialization. There can be no assurance that FDA or other
regulatory authority approval for pleconaril or any other product candidate
under development by ViroPharma will be granted on a timely basis or at all.
Even if approved, there can be no assurance that pleconaril will achieve market
acceptance. These factors, and other factors that could cause future results to
differ materially from the expectations expressed in this press release,
include, but are not limited to, those described in ViroPharma's most recent
Registration Statement on Form S-3 filed with the Securities and Exchange
Commission. The forward-looking statements contained in this press release may
become outdated over time. ViroPharma does not assume any responsibility for
updating any forward-looking statements.
Item 7 - Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits
Exhibit No. Description
----------- -----------
99 ViroPharma Press Release dated August 29, 2000
<PAGE>
Signatures
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
ViroPharma Incorporated
Date: April 29, 2000 By: /s/ Michel de Rosen
-------------------
Michel de Rosen
President and Chief Executive Officer
<PAGE>
Index to Exhibits
Exhibit No. Description
----------- -----------
99 ViroPharma Press Release dated August 29, 2000
